Search

The undesired precipitation of minerals from solution poses challenges in various industrial and domestic applications, including water treatment, desalination, dishwashers and boilers. To mitigate this, threshold inhibitors - small quantities of water-soluble additives—are commonly employed to inhibit the precipitation of inorganic phases. However, concerns about the persistence of traditional additives like phosph(on)ates) in natural environments and stricter regulations warrant the development of more sustainable alternatives. We present a high-throughput approach using a UV-Vis spectrophotometer and automated data analysis to assess the scale inhibiting potential of numerous candidates and their combinations. The robustness and versatility of this method were validated by measuring the kinetics of alkaline-earth metal carbonates precipitating from simulated hard waters and seawaters across an extended range of experimental parameters. This approach allows for straightforward evaluation and quantification of each antiscaling additive's effectiveness and operational range, enabling direct comparison of different additives and blends of additives. Moreover, it facilitates the study of scaling processes in both bulk solutions and at liquid/solid interfaces. By providing a rapid and reliable means of screening potential additives and formulations, our versatile toolbox will expedite the identification of effective scale inhibitors, thereby contributing to the advancement of sustainable practices in various industries reliant on water treatment and mineral precipitation control. [ABSTRACT FROM AUTHOR]

Purpose: In 2007, a large goat-farming-associated Q fever outbreak occurred in the Netherlands. Data on the clinical outcome of Dutch Q fever patients are lacking. The current advocated follow-up strategy includes serological follow-up to detect evolution to chronic disease and cardiac screening at baseline to identify and prophylactically treat Q fever patients in case of valvulopathy. However, serological follow-up using commercially available tests is complicated by the lack of validated cut-off values. Furthermore, cardiac screening in the setting of a large outbreak has not been implemented previously. Therefore, we report here the clinical outcome, serological follow-up and cardiac screening data of the Q fever patients of the current ongoing outbreak. Methods: The implementation of a protocol including clinical and serological follow-up at baseline and 3, 6 and 12 months after acute Q fever and screening echocardiography at baseline. Results: Eighty-five patients with acute Q fever were identified (male 62%, female 38%). An aspecific, flu-like illness was the most common clinical presentation. Persistent symptoms after acute Q fever were reported by 59% of patients at 6 months and 30% at 12 months follow-up. We observed a typical serological response to Coxiella burnetii infection in both anti-phase I and anti-phase II IgG antibodies, with an increase in antibody titres up to 3 months and a subsequent decrease in the following 9 months. Screening echocardiography was available for 66 (78%) out of 85 Q fever patients. Cardiac valvulopathy was present in 39 (59%) patients. None of the 85 patients developed chronic Q fever. Conclusions: Clinical, serological and echocardiographic data of the current ongoing Dutch Q fever outbreak cohort are presented. Screening echocardiography is no longer part of the standard work-up of Q fever patients in the Netherlands. [ABSTRACT FROM AUTHOR]